Introduction {#S0001}
============

The increasing HIV diversity and evolution of circulating and unique recombinants forms (CRFs and URFs) pose a major threat to accurate identification of the circulating HIV strains in an epidemic. This has an impact on development, implementation and maintenance of effective preventive and treatment intervention strategies including vaccine development \[[@CIT0001],[@CIT0002]\]. Due to high genetic heterogeneity, methods for universal amplification and sequencing of diverse HIV-1 subtypes remain inadequate \[[@CIT0003]\]. Regularly, a smaller gene portion is used to characterize the subtype, which limits accurate identification of the HIV-1 strains, especially for the recombinant forms. Our earlier study identified a significantly higher prevalence of recombinant forms when two or more genes were used for subtyping \[[@CIT0004]\]. Moreover, using a smaller portion of the genome limits the identification of epidemiological signatures and recombination hot spots \[[@CIT0005]\], adaptations in a host population and immune recognition at whole genome level \[[@CIT0006],[@CIT0007]\].

In current clinical practice of the genotypic resistance testing (GRT), most of the commercial or in-house assays provide information about the HIV-1 drug resistance mutations (DRMs) restricted to full-length protease (PR) (1--99) and partial reverse transcriptase (RT) (1--335). However, a growing body of scientific evidence suggests the role of connection domain mutations, for example, N348I \[[@CIT0008]\], in conferring resistance to reverse transcriptase inhibitors (RTIs). Furthermore, distal non-drug target HIV-1 Gag mutations have been described to confer strong resistance to protease inhibitor (PI) \[[@CIT0009],[@CIT0010]\].

Several studies have attempted to develop protocols for HIV-1 near full-length genome (HIV-NFLG) sequencing. However, most of the studies were restricted to sequencing of single subtypes \[[@CIT0002],[@CIT0011]\] or identification of CRFs \[[@CIT0012],[@CIT0013]\]. Moreover, genetic material was mainly derived from cultured cells or as proviral DNA from blood mononuclear cells \[[@CIT0014]--[@CIT0016]\]. Data directly from plasma samples are scarce, albeit they are routinely used in clinical drug resistance testing \[[@CIT0002],[@CIT0017]\] and reflect the most recent viral population in the host \[[@CIT0018]\].

Among the HIV-1 groups, the M-group dominates in global infections. Among the M-group subtypes, HIV-1 subtype C (HIV-1C); HIV-1A (A1 and A2); HIV-1B; CRF02_AG and CRF01_AE account for nearly 84% of the global infections \[[@CIT0019]\]. In our recent study from the Swedish InfCare cohort based on the *pol* gene, we identified a highly diverse HIV-1 epidemic dominated by HIV-1B (47%), HIV-1C (18%) and CRF01_AE (12%) \[[@CIT0020]\].

The aim of the present study was to develop a simple, cost and labour-efficient protocol for HIV-NFLG sequencing for diverse HIV-1 subtypes. This protocol could be used routinely in large-scale population-based molecular epidemiological studies. Additionally, this protocol can also be implemented for extended drug resistance genotyping with full-length Gag for predictors of PI-DRMs, full-length PR and RT, Integrase (IN) for Integrase Inhibitor (INI) as well as genotypic co-receptor tropism testing for co-receptor antagonists. Here, we amplified, sequenced and assembled HIV-1B, HIV-1C, CRF01_AE and CRF02_AG NFLG. Therefore, this protocol might potentially serve as a single tool for both epidemiological and clinical studies, independent of HIV-1 subtypes.

Methods {#S0002}
=======

Ethical consideration {#S0002-S20001}
---------------------

Ethical permissions were obtained from the Regional Ethics Committee Stockholm (Dnr: 2006/1367-31/4). The patient information was anonymized and de-linked prior to analysis. Single peripheral blood samples were obtained during the routine viral load testing and GRT using ViroSeq™ HIV-1 Genotyping System (Celera Diagnostics, Alameda, CA, USA).

Patients material and RNA extraction {#S0002-S20002}
------------------------------------

The patients were followed-up at the Infectious Disease Clinic at Karolinska University Hospital, Stockholm, Sweden, as part of a large cohort, InfCare HIV \[[@CIT0020]\]. Based on *pol* gene subtyping, a total of 30 samples from four different HIV-1 subtypes (HIV-1B (*n*=10), HIV-1C (*n*=10), 01_AE (*n*=5) and 02_AG (*n*=5)) were attempted for HIV-NFLG sequencing. Viral RNA was extracted using QIAamp viral RNA extraction kit (Qiagen, Hilden, Germany) from 140 µl of plasma. RNA was quantified and purity checked using NanoDrop (Thermo Scientific, DE, USA) and stored at −80°C until used. Among the 30 samples, four samples gave A260/A280 and 260/A230 ratio below one and were therefore excluded from the study.

Primer and cDNA synthesis {#S0002-S20003}
-------------------------

The near full-length genome from the samples was amplified in two fragments using nested and semi-nested polymerase chain reactions (PCR) with seven sets of primers numbered as HXB2 \[GenBank:K03455\] co-ordinates ([Figure 1](#F0001){ref-type="fig"}a and [Table 1](#T0001){ref-type="table"}). First-strand cDNA synthesis was performed using the SuperScript^®^ III RT enzyme (Invitrogen, Life Technologies, MA, USA). For fragment 1 Gag-Vpu (herein F1~Gag-Vpu~), cDNA was synthesized with the primer 6352R (10 pmol) and for fragment 2, Tat-3LTR (herein F2~Tat-3LTR~), an oligo (dT)~18~ primer (50 pmol) (Thermo Scientific) was used. A first master mix of 5 µl extracted viral RNA was combined with 1 µl of 10 mM dNTP mix, 1 µl of 6352R or oligo(dT)~18~ primer and 5 µl of PCR grade water. The reaction mix was heated to 65°C for five minutes and immediately placed on ice for two minutes. A second master mix consisting of 4 µl of 5× First-Strand Buffer (250 mM Tris-HCl, 375 mM KCl, 15 mM MgCl~2~), 1 µl 0.1 M DTT, 1 µl of RiboLock RNase inhibitor (40 U/µl; Thermo Scientific) and 2 µl of SuperScript-III RT (200 U/µl) was subsequently added to the first mastermix. The final 20 µl reaction mix was then incubated at 25°C for five minutes followed by 55°C for one hour and finally 70°C for 10 minutes to terminate the reaction.

![Amplification strategy of HIV-1 NFLG. (a) HIV-1 gene map in HXB2 \[GenBank:K03455\] co-ordinates Adapted from Los Alamos Database ([www.hiv.lanl.gov](http://www.hiv.lanl.gov)). (b) The locations of all primers used for cDNA synthesis, nested and semi-nested PCR are shown. The 8.8 kb genome is amplified into two fragments: fragment 1, 5.5 kb (gag-vpu) and fragment 2, 3.7 kb (vif-3′-LTR) with 400 bp overlap. (c) Representative amplification of all four subtypes is presented.](JIAS-18-20035-g001){#F0001}

###### 

Primers used in this study

  Primer_ID               Seq (5′→3′)                     HXB2 position   Ref.
  ----------------------- ------------------------------- --------------- ---------------------------
  Amplification primers                                                   
  F1~Gag-Vpu~                                                             
   0682F                  TCTCTCGACGCAGGACTCGGCTTGCTG     0682→0708       \[[@CIT0004],[@CIT0021]\]
   0776F                  CTAGAAGGAGAGAGAGATGGGTGCGAG     0776→0800       \[[@CIT0004]\]
   6352R                  GGTACCCCATAATAGACTGTRACCCACAA   6352→6324       \[[@CIT0017]\]
   6231R                  CTCTCATTGCCACTGTCTTCTGCTC       6231→6207       \[[@CIT0017]\]
  F2~Vif-3LTR~                                                            
   5550F                  AGARGAYAGATGGAACAAGCCCCAG       5550→5574       \[[@CIT0017]\]
   5861F                  TGGAAGCATCCRGGAAGTCAGCCT        5861→5884       \[[@CIT0017]\]
   9555R                  TCTACCTAGAGAGACCCAGTACA         9555→9533       Present study
  Sequencing primers                                                      
  F1~Gag-Vpu~                                                             
   0776F                  CTAGAAGGAGAGAGAGATGGGTGCGAG     0776→0800       \[[@CIT0004]\]
   1231F                  TCACCTAGAACTTTRAATGCATGGG       1231→1255       Present study
   1817F                  TAGAAGAAATGATGACAG              1817→1834       \[[@CIT0022]\]
   2586F                  AAGCCAGGAATGGATGGCCCA           2586→2606       \[[@CIT0023]\]
   2713R                  GGATTTTCAGGCCCAATTTTTG          2713→2692       Present study
   3885R                  CTGCTCCATCTACATAGAA             3885→3867       \[[@CIT0024]\]
   4350R                  CACAGCTAGCTACTATTTCTTTTGC       4350→4326       \[[@CIT0024]\]
   4900F                  GGGTTTATTACAGGGACAGCAGAG        4900→4923       \[[@CIT0025]\]
   5066R                  ATCATCACCTGCCATCTGTTTTCCAT      5066→5041       \[[@CIT0026]\]
   6231R                  CTCTCATTGCCACTGTCTTCTGCTC       6231→6207       \[[@CIT0017]\]
  F2~Vif-3LTR~                                                            
   5861F                  TGGAAGCATCCRGGAAGTCAGCCT        5861→5884       \[[@CIT0017]\]
   6559F                  GGGATCAAAGCCTAAAGCCATGTGTAA     6559→6585       \[[@CIT0022]\]
   7002F                  TTRTTAAATGGTAGTATAGC            7002→7021       Present study
   7373R                  GAAAAATTCTCCTCYACAATTAAA        7373→7350       Present study
   7761F                  GTGGGAATAGGAGCTGTGTTCCTTGGG     7761→7787       \[[@CIT0022]\]
   8445R                  CTCTCTCTCCACCTTCTTCTTC          8445→8424       \[[@CIT0022]\]
   9555R                  TCTACCTAGAGAGACCCAGTACA         9555→9533       Present study

Source of the primers are given. The primer IDs are changed from the original for the ease of identification. The numbering is as per HXB2 (K03455).

NFLG PCR and sequencing {#S0002-S20004}
-----------------------

All PCR reactions were performed with high fidelity KAPA HiFi HotStart ReadyMix (2×) (KAPA Biosystem, MA, USA) with 15 pmol of each primer in 50 µl total volume. For F1~Gag-Vpu~, the first round PCR was performed with 0682F and 6352R primers and was followed by the second round nested with 0776F and 6231R primers, which yielded an amplicon of approximately 5.5 kb ([Figure 1](#F0001){ref-type="fig"}b). The condition for both PCRs was as follows: initial denaturation at 95°C for five minutes followed by 30 cycles of 98°C for 20 sec, 65°C for 15 sec and 72°C for three minutes and final extension at 72°C for five minutes. The F2~Tat-3LTR~ fragment was amplified in a semi-nested manner with the first and second round forward primers 5550F and 5831F, respectively, with a common reverse primer 9555R, yielding a 3.7 kb amplicon ([Figure 1](#F0001){ref-type="fig"}b). The condition for both the PCRs was as follows: initial denaturation at 95°C for five minutes followed by 30 cycles of 98°C for 20 sec, 65°C for 15 sec and 72°C for two minutes and final extension at 72°C for five minutes. The PCR amplicon was gel purified using QIAamp Gel Extraction Kit (Qiagen). Sequencing was performed with a set of 17 primers ([Table 1](#T0001){ref-type="table"}). Representative PCR amplification of all the four subtypes was presented in [Figure 1](#F0001){ref-type="fig"}c.

Sequence assembly, visualization and quality control {#S0002-S20005}
----------------------------------------------------

The sequencing primers were designed in such a way that there will be 100 bases overlapping with 800 bp sequencing read ([Table 1](#T0001){ref-type="table"}). The sequencing was performed with the Applied Biosystems^®^ 3730xl DNA Analyzer (Life Technologies, CA, USA). The sequences were auto-clipped with a quality score ≥10. CAP3 Sequence Assembly Program with default parameter was used to assemble the final sequence from all available contigs \[[@CIT0027]\]. Due to high genetic variability, only the major peak was considered in the consensus sequence. Single-base frame shifts due to sequencing errors were curated manually after observation of the chromatogram or alignment with the subtype-specific consensus sequences in ClustalX2 \[[@CIT0028]\]. A multiple sequence alignment against the HXB2 reference genome was generated and analyzed with an in-house Perl script (Supplementary file 1) that recognizes the nucleotide changes from the HXB2 sequence \[GenBank:K03455\] and creates a corresponding number code as per HXB2 co-ordinates. The resulting matrix was plotted using the TraMineR package \[[@CIT0029]\] in R version 3.1.2 \[[@CIT0030]\]. Sequence quality control was performed using Quality Control Tool available in Los Alamos database ([www.hiv.lanl.gov/](http://www.hiv.lanl.gov/)) and submitted to GenBank under accession nos. KP411822 to KP411845.

Subtyping, drug resistance and co-receptor tropism {#S0002-S20006}
--------------------------------------------------

HIV-1 subtyping was performed with COMET-HIV, which uses adaptive context-based modelling for ultrafast HIV-1 subtype identification \[[@CIT0031]\]. A maximum likelihood phylogenetic tree with reference sequences was generated in MEGA6 software \[[@CIT0032]\] using a General Time Reversible (GTR) model with inverse gamma distribution. The reference sequences were downloaded from Los Alamos database ([www.hiv.lanl.gov](http://www.hiv.lanl.gov)). GRT was performed with whole *pol* gene that provides DRM profile of PR, RT and IN. The results were compared with the ViroSeq™ HIV-1 Genotyping System (Life Technologies), which provide DRM profile of full PR and first 335 amino acids of RT. Co-receptor tropism analysis was performed using Geno2pheno~\[co-receptor\]~ with 10% false-positive rate \[[@CIT0033]\].

Results {#S0003}
=======

The patients (*n*=26) demographic and clinical characteristics along with the amplification proficiency are given in [Table 2](#T0002){ref-type="table"}.

###### 

Demographic and clinical parameters and amplification of HIV-1 fragment of the study samples

  PID        Age   Sex      Viral load^[a](#TF0001){ref-type="table-fn"}^   CD4^[a](#TF0001){ref-type="table-fn"}^   Therapy      Country of transmission   Route of transmission^[a](#TF0001){ref-type="table-fn"}^   F1~Gag-Vpu~   F2~vif-3LTR~
  ---------- ----- -------- ----------------------------------------------- ---------------------------------------- ------------ ------------------------- ---------------------------------------------------------- ------------- --------------
  SE600001   51    Male     1,905,461                                       4                                        Naïve        Sweden                    IVDU                                                       \+            \+
  SE600012   39    Male     707,946                                         190                                      Naïve        Sweden                    MSM                                                        \+            \+
  SE600023   41    Male     194,984                                         150                                      Naïve        Sweden                    Heterosexual                                               \+            \+
  SE600034   52    Male     3,467,369                                       220                                      Naïve        Sweden                    MSM                                                        \+            \+
  SE600035   44    Female   309,030                                         260                                      Naïve        Sweden                    IVDU                                                       \+            \+
  SE600046   50    Male     6,606,934                                       9                                        Naïve        NA                        MSM                                                        \+            \+
  SE600057   45    Male     50,400                                          180                                      Naïve        Sweden                    Heterosexual                                               \+            \+
  SE600063   45    Female   7600                                            316                                      Naïve        Sweden                    Heterosexual                                               \+            \+
  SE600068   40    Female   1300                                            421                                      Naïve        Sweden                    NA                                                         −             \+
  SE600099   27    Female   1120                                            510                                      Naïve        Sweden                    Heterosexual                                               \+            −
  SE600108   35    Male     150,000                                         270                                      Naïve        Sweden                    IVDU                                                       \+            \+
  SE600119   39    Male     158,000                                         184                                      Naïve        Ethiopia                  Heterosexual                                               \+            \+
  SE600210   42    Male     338,844                                         133                                      Naïve        Ethiopia                  Heterosexual                                               \+            \+
  SE600311   58    Male     3990                                            110                                      Experience   Ethiopia                  Heterosexual                                               \+            \+
  SE600412   58    Male     18,400                                          300                                      Naïve        Eritrea                   Heterosexual                                               \+            \+
  SE600213   25    Female   110,000                                         169                                      Naïve        Ethiopia                  Heterosexual                                               \+            \+
  SE600314   40    Female   219,000                                         400                                      Naïve        Zimbabwe                  Heterosexual                                               \+            \+
  SE600415   30    Male     575,000                                         125                                      Naïve        Eritrea                   Heterosexual                                               \+            \+
  SE600122   38    Female   6580                                            460                                      Naïve        Eretria                   Heterosexual                                               \+            \+
  SE600516   37    Female   1,000,000                                       304                                      Naïve        Sweden                    Heterosexual                                               \+            \+
  SE601017   34    Female   2,300,000                                       16                                       Naïve        Thailand                  Heterosexual                                               \+            \+
  SE601018   35    Female   260,000                                         350                                      Naïve        Thailand                  Heterosexual                                               \+            \+
  SE601021   40    Female   40,800                                          249                                      Naïve        Thailand                  NA                                                         \+            \+
  SE602019   41    Female   129,000                                         400                                      Naïve        Senegal                   Blood transfusion                                          \+            \+
  SE602020   24    Female   162,000                                         90                                       Experience   Cameroon                  Heterosexual                                               \+            \+
  SE602024   35    Female   3060                                            360                                      Naïve        Cameroon                  Heterosexual                                               \+            \+

Viral load in copies/ml, CD4 in cells/mm^3^. IVDU: intravenous drug user; MSM: men who have sex with men; NA: not available.

Among the 26 samples with viral loads ranging from 1120 to 6,606,934 copies/ml, both PCR fragments were amplified and sequenced from 24 samples (efficiency 92%). In two samples with viral loads below 2000 copies/ml (1300 and 1120 copies/ml respectively), either one of the fragments was not amplified. Amplification was successful in all remaining samples with the lowest viral load being 3060 copies/ml.

For F1~Gag-Vpu~, 10 primers were used which gave complete coverage from the HXB2 positions 790 to 6200. The F2~Tat-3LTR~ amplicon is considerably shorter (\~3.7 kb) but still required seven sequencing primers. This was due to the high intra-individual HIV-1 genetic diversity and the presence of poly-A stretches in the region as poly-A stretches can abruptly terminate the sequencing read.

The phylogenetic analysis identified the same subtype as identified by the *pol* region with 10 as HIV-1C, 8 as HIV-1B and 3 each as 01_AE and 02_AG ([Figure 2](#F0002){ref-type="fig"}a). The sequence variability of the 24 samples compared to HXB2 sequence is presented in [Figure 2](#F0002){ref-type="fig"}b. This indicates higher sequence variability in the *env* region and the subtype-specific signatures over the genome specifically in the Gag-p6 region.

![Phylogenetic and variability analysis of sequenced Swedish HIV-1 strains. (a) Maximum likelihood phylogenetic tree with reference HIV-1 sequences downloaded from Los Alamos Database. Four subtypes are indicated: HIV-1B (dark blue), HIV-1C (orange), CRF01_AG (green) and CRF02_AG (purple). The Swedish strains are indicated with filled circle with a respective colour. (b) Genetic diversity of HIV-1 subtypes: all the 24 HIV-1 genomes were aligned with reference to HXB2 \[GenBank:K03455\]. For each sequence, every nucleotide differing from the reference HXB2 strain (mutation) is shown as a green line, an insertion is shown in orange, and a deletion is shown in purple. The top panel shows the open-reading frame of HIV-1 genes: *gag* (violet), *pol* (lemon green), *vif* (pink), *vpr* (light red), *tat exon 1 and 2* (black), *rev exon 1 and 2* (grey), *vpu* (cyan), env (light yellow) and nef (green).](JIAS-18-20035-g002){#F0002}

DRM analysis based on the ViroSeq™ HIV-1 Genotyping System and the current HIV-NFLG assay is presented in [Table 3](#T0003){ref-type="table"}. It should be noted that the HIV-NFLG and the ViroSeq™ showed \>99% concordance at 71 DRM positions (PR: 33 positions and RT: 38, excluding N348I, which is not detected by ViroSeq™) in 24 samples (total codon analysis 1704 and three mismatch). In two samples, ViroSeq™ identified PI mutation L10IL (SE600314) and RTI mutations Y318YF (SE602020) in contradiction to the current assay. On the contrary, the V11I mutation was detected by NFLG in one sample (SE600057) but not by ViroSeq™. In two samples, NFLG identified additional N348I mutations due to an extended genomic coverage. Moreover, the current assay potentially can identify the INI-DRMs. The co-receptor tropism identified 18 CCR5-tropic viruses and six as CXCR4-tropic virus ([Table 3](#T0003){ref-type="table"}).

###### 

Comparative drug resistance analysis of current protocol and ViroSeq™ genotypic resistance testing

             ViroSeq genotypic system   Whole genome sequencing                                                                                                
  ---------- -------------------------- ------------------------- ------- -------------------------- ------ ------------ ------- -------------- ------ ------- -------
  SE600001   None                       None                      None    None                       None   None         None    None           None   None    CCR5
  SE600012   None                       None                      None    None                       None   None         None    None           None   None    CXCR4
  SE600023   None                       None                      T215S   None                       None   None         T215S   None           None   None    CCR5
  SE600034   None                       None                      None    V90I                       None   None         None    V90I           None   None    CCR5
  SE600035   None                       None                      None    None                       None   None         None    None           None   None    CCR5
  SE600046   None                       None                      None    None                       None   None         None    None           None   None    CXCR4
  SE600057   None                       None                      None    None                       None   **V11I**     None    None           None   E157Q   CCR5
  SE600063   None                       None                      None    None                       None   None         None    None           None   None    CXCR4
  SE600108   None                       None                      None    None                       None   None         None    **N348I**      None   None    CCR5
  SE600119   None                       None                      None    None                       None   None         None    None           None   None    CCR5
  SE600210   None                       None                      None    None                       None   None         None    None           None   None    CCR5
  SE600311   None                       None                      None    V90I                       None   None         None    V90I           None   None    CCR5
  SE600412   None                       None                      None    None                       None   None         None    None           None   None    CCR5
  SE600213   None                       None                      None    None                       None   None         None    None           None   None    CCR5
  SE600314   None                       **L10IL**                 None    E138A                      None   None         None    E138A          None   None    CCR5
  SE600415   None                       None                      None    None                       None   None         None    **N348I**      None   None    CCR5
  SE600122   None                       V11I                      None    None                       None   V11I         None    None           None   None    CCR5
  SE600516   None                       None                      None    None                       None   None         None    None           None   None    CCR5
  SE601017   None                       None                      None    None                       None   None         None    None           None   L74I    CXCR4
  SE601018   None                       None                      None    E138A                      None   None         None    E138A          None   None    CCR5
  SE601021   None                       None                      None    None                       None   None         None    None           None   None    CXCR4
  SE602019   None                       L10I, K20I                None    None                       None   L10I, K20I   None    None           None   None    CCR5
  SE602020   None                       K20I                      M184V   V106A, F227L, **Y318FY**   None   K20I         M184V   V106A, F227L   None   None    CXCR4
  SE602024   None                       K20I                      None    None                       None   K20I         None    None           None   None    CCR5

The mismatches are marked in bold.

Discussion {#S0004}
==========

In the present study, we have developed a simple, labour and time-efficient HIV-NFLG sequencing protocol that can be used for large-scale molecular epidemiological studies. This assay can identify the phylogenetic transmission cluster in a local HIV-1 epidemic. Therefore, it has a potential role in the prevention of HIV-1 transmission in the high-risk groups from a public health perspective. Moreover, the assay extends the genotypic GRT to cover all HIV-1 drug target sites (PR inhibitors, RTIs, IN and fusion inhibitors). It also includes genotypic co-receptor tropism analysis and genetic analysis of the non-drug target sites that potentially affect the drug efficiency as well as resistance (e.g. Gag).

Molecular epidemiological studies often use smaller gene fragments that can potentially underestimate the event of recombination. Our earlier study showed significant increase in recombinants when two or more genes from different parts of the HIV-1 genome (e.g. *gag, pol* and *env*) were used \[[@CIT0004]\]. Therefore, the use of NFLG is ideal to be used as a tool for HIV-1 subtyping \[[@CIT0034]\]. It also enables an understanding of the dynamics of the HIV pandemic at a population level \[[@CIT0003]\]. Earlier studies that developed full-length genome are either expensive, time consuming or hampered by low throughput that is often restricted to one HIV-1 subtype \[[@CIT0002]\]. A HIV-NFLG sequencing protocol from plasma viral RNA has been developed using two or three fragments to cover 9 kb genome \[[@CIT0017]\]. However, the method was limited by its efficiency in samples having a viral load \<10,000 copies/ml and a subtype-independent applicability was not mentioned. If a high-quality RNA sample is provided, NFLG sequences from patients with viral loads as low as 3000 copies/ml can be obtained, which is a great advantage of the presented assay compared to the earlier method \[[@CIT0017]\].

Most importantly, the current method can detect four major subtypes and recombinant forms (HIV-1B, HIV-1C, 01_AE and 02_AG), which are responsible for \>80% of global infections when combined \[[@CIT0019]\]. The method can be potentially applied to all major pure and recombinant HIV-1 strains as the primers applied here had \>95% sequence identity to them. Recently, a universal amplification protocol has been developed that amplifies HIV-1 genome in four PCR fragments followed by sequencing in a next generation sequencing (NGS) platform \[[@CIT0003]\]. However, the method is more labour-intensive and the application of the method is limited in low- and middle-income countries (LMICs) due to limited availability of NGS and corresponding experts to run the assays. The calculated costs for NGS strongly depend on the number of samples processed and increase if only a few numbers of samples have to be analyzed. In our current NFLG method, the cost per sample is between \$130 and \$140 and even one sample can be run without any change in effective cost. The overall time taken for the method is five days.

The current method can also be applied for genotypic resistance testing as it showed high concordance in determining the DRM compared to gold standard ViroSeq™ System. Additionally, it can determine clinically important N348I that confers resistance to RTI \[[@CIT0008]\]. Recently, a single assay for HIV-1 GRT and co-receptor tropism assay, based on deep sequencing, has been developed \[[@CIT0035]\]. Though the assay is high throughput, the application of the method is limited in LMICs, due to limited availability of NGS in those settings. However, with this current method, in a single assay it is now possible to determine PI, RTI and INI resistance mutations and co-receptor tropism in LMICs also. Finally, Gag has shown to act synergistically to confer resistance to PIs \[[@CIT0009],[@CIT0010]\]. The insertions in Gag-p6 have recently shown to be associated with PI-therapy failure in Indian HIV-1C viruses \[[@CIT0036]\]. The current method is also helpful in determining the full Gag including p6 region.

Our study has certain technical aspects that merit comments. First, the quality of RNA is important for successful amplification. Therefore, highly lipemic or lysed samples should not be used. Second, the sequencing of the Env region may require more primers \[[@CIT0022]\]. This is due to higher occurrence of poly-A stretches in the *env* variable regions (V1 to V5; more specifically in the V4 region), which can suddenly stop the sequencing reaction. Third, in two positions mixed populations were detected by ViroSeq™ but not by NFLG. This kind of results was also noted in earlier studies \[[@CIT0037],[@CIT0038]\] and might be due to the variant calling. The method is less efficient in samples with viral load \<3000 copies/ml. Furthermore, extensive mutations in the primer binding sites can result in failure of amplification as observed in most HIV-diagnostic assays. However, a major merit of this assay is its subtype independency. In the current study, the samples were from patients who got HIV infected in different countries -- Sweden, Zimbabwe, Ethiopia, Thailand, Senegal, Cameroon and Eritrea -- with four major subtypes. Another important factor is the use of this method in clinical management of drug resistance. The input plasma sample volume is only 140 µl. Thus, no additional blood sample is required and the assay can be merged with routine viral load and CD4 testing.

Conclusions {#S0005}
===========

In conclusion, we demonstrated a subtype-independent HIV-NFLG sequencing method that is a simple, cost and labour-efficient and promising approach. The method can be used in large-scale population-based molecular epidemiological studies that can identify the HIV-1 recombinant forms more accurately as well as population dynamics of HIV-1 spread. It can also be used in extended genotypic resistance testing that can evaluate DRMs in PR, RT and IN genes. Genotypic co-receptor tropism for evaluation of co-receptor antagonist usage can also be done in one single assay. Therefore, the application of this method in clinical care can improve patient management strategies through the accurate identification the strains. A better understanding of the population dynamics of HIV-1 within pandemics could enable the development of an effective intervention for control and prevention.
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